CAMP4 Therapeutics Corporation (CAMP)

Nasdaq: CAMP · Pharmaceutical Preparations · Cambridge, MA · filing with the SEC since 2018

Full chart Alerts Compare

Grade5.1

◀ Past 5.4● Present 4.0▶ Future 6.0

3 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The grade of CAMP4 Therapeutics Corporation

Nine metrics read from its own filings, by tense

Headline grade

5.1/10

◀ Past5.425% of the headline

● Present4.035% of the headline

▶ Future6.040% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 6 read as filed from the record and 3 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

5.4/1025% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed

8.2/10

Has it survived what it has been through?

No warning events in its filings since 2018.

weight 22% of this tense · 82nd percentile among 497 sector filers · read for itself

From the record

CAMP4 Therapeutics Corporation's filings since 2018 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed

7.7/10

What has it actually done, year after year?

+215.9% a year over 3 filed years; profitable in 0 of 3.

weight 45% of this tense · 77th percentile among 323 sector filers · read for its customers

From the record

CAMP4 Therapeutics Corporation's 3 filed years say what it did: revenue went from $350 thousand in fiscal 2023 to $3 million in fiscal 2025, up 215.9% a year; it rose in 2 of 2 years; it never fell from a peak; net income was positive in 0 of 3 of those years (its annual reports).

What it rests on

revenue growth over the filed span215.9%top 2% of its family
the share of years revenue rosetop 8% of its family
the share of filed years with a profitbottom 27% of its family
the deepest fall from a revenue peak0.0%top 10% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate

0.4/10

How has it treated the people who own it?

SI estimate 0.4/10, confidence 35 of 100 (one part).

weight 33% of this tense · 4th percentile among 464 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: Read from one part only, the share count over the years, which ranks in the bottom 4% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read: Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned: one part: the share count over the years, the one part on file, ranked among 464 in its family.
Confidence: 35 of 100
What would change it: A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: CAMP4 Therapeutics Corporation's shareholder treatment is put at 0.4 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 4% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

4.0/1035% of the headline grade · 2 of 3 filed, 1 estimated

Financial health

as filed

1.9/10

Is it financially healthy right now?

ROE -169%: lost 169¢ per shareholder dollar. Leverage 60%: owes 60¢ per asset dollar.

weight 45% of this tense · 19th percentile among 473 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, CAMP4 Therapeutics Corporation lost about 169 cents for every dollar of shareholders' money. Leverage: it owed about 60 cents per dollar of assets, and net share issuance: its share count grew 547.8% over the year (the filed statements).

What it rests on

what it owes per dollar of assetsbottom 28% of its family
return on equitybottom 19% of its family
the share count against the year beforebottom 9% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed

4.9/10

How strong is its position in its industry?

bottom 49% of 315 in its family; net margin -2298.5%.

weight 22% of this tense · 49th percentile among 315 sector filers · read for its customers

From the record

CAMP4 Therapeutics Corporation's standing among 315 graded names in its industry family: revenue of $3 million in fiscal 2025 ranks in the bottom 32% by size; a net margin of -2298.5% ranks in the bottom 22%; revenue growth of 215.9% a year over the last 2 filed years ranks in the top 7% (its annual reports).

What it rests on

revenue against the family$3.5Mbottom 32% of its family
net margin-2298.5%bottom 22% of its family
three-year revenue growth215.9%top 7% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

SI estimate

6.3/10

What are the people in charge doing?

SI estimate 6.3/10, confidence 35 of 100 (one part).

weight 33% of this tense · 63rd percentile among 415 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: Read from one part only, officer and director changes on Form 8-K over three years, against the people in charge, which ranks in the top 37% of 415 in its family; the record of its people begins on 2024-10-10 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 2.1 years and cannot see past it; a floor under five years is not read as years in charge.
What the record cannot read: The record of its people begins on 2024-10-10 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 2.1 years and cannot see past it; a floor under five years is not read as years in charge.
How it was reasoned: one part: officer and director changes on Form 8-K, against the people in charge, the one part on file, ranked among 415 in its family.
Confidence: 35 of 100
What would change it: A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: CAMP4 Therapeutics Corporation's leadership is put at 6.3 of 10 with a confidence of 35 of 100, because read from one part only, officer and director changes on Form 8-K over three years, against the people in charge, which ranks in the top 37% of 415 in its family; the record of its people begins on 2024-10-10 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 2.1 years and cannot see past it; a floor under five years is not read as years in charge. A filing that carries the missing parts replaces this estimate with the filed reading.

▶ Future

What are they set up to do next?

6.0/1040% of the headline grade · 2 of 3 filed, 1 estimated

Room to expand

as filed

6.8/10

How much room does it have to grow?

top 32% of 273 in its family for room to expand.

weight 33% of this tense · 68th percentile among 273 sector filers · read for itself

From the record

CAMP4 Therapeutics Corporation's room to grow, from the newest filed statements (fiscal 2025): cash of $112 million against no long-term debt tagged leaves 94.9% of its assets as net cash, top 5% of its family; cash from operations less capital spending is -852.8% of revenue (bottom 28%); research spending of 1092.1% of revenue (top 20%) (its annual report).

What it rests on

cash less debt against assets94.9%top 5% of its family
cash from operations less capital spending against revenue-852.8%bottom 28% of its family
research spending against revenue1092.1%top 20% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed

5.7/10

What could actually drive growth from here?

top 43% of 306 in its family for growth drivers.

weight 45% of this tense · 57th percentile among 306 sector filers · read for its customers

From the record

CAMP4 Therapeutics Corporation's growth drivers, from the filed years to fiscal 2025: revenue grew 215.9% a year over the last three filed years against 215.9% over all 3, speeding up (top 40% of its family); the newest year grew 437.1% (top 7%); research spending grew -3% a year (bottom 42%); capital spending grew -35.8% a year (bottom 32%) (its annual reports). CAMP4 Therapeutics Corporation tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

three-year growth against the whole span+0.0 points a yeartop 40% of its family
the newest year's revenue growth437.1%top 7% of its family
three-year growth of research spending-3.0%bottom 42% of its family
three-year growth of capital spending-35.8%bottom 32% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

SI estimate

5.3/10

Did its newest year beat what its own record pointed to?

SI estimate 5.3/10, confidence 20 of 100 (family median).

weight 22% of this tense · 50th percentile among 234 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: The record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change, so the desk assumes the typical reading of its industry family, the median of 234 members with one.
What the record cannot read: The record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change.
How it was reasoned: family median, 234 readings behind it.
Confidence: 20 of 100
What would change it: Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: CAMP4 Therapeutics Corporation's expectations vs reality is put at 5.3 of 10 with a confidence of 20 of 100, because the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change, so the desk assumes the typical reading of its industry family, the median of 234 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton CAMP · research, not advice